Abstract
Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary β amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aβ- promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aβ neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the “in vivo” mouse model of AD, Tg2576, which also expresses human AβPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Keywords: IL-3, neuroprotection, Tau, Tg2576, Aβ, neurodegeneration, cytokines, caspase 3.
Current Alzheimer Research
Title: IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration
Volume: 7 Issue: 7
Author(s): A. Zambrano, C. Otth, R.B. Maccioni and I.I. Concha
Affiliation:
Keywords: IL-3, neuroprotection, Tau, Tg2576, Aβ, neurodegeneration, cytokines, caspase 3.
Abstract: Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary β amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aβ- promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aβ neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the “in vivo” mouse model of AD, Tg2576, which also expresses human AβPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Export Options
About this article
Cite this article as:
Zambrano A., Otth C., Maccioni R.B. and Concha I.I., IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration, Current Alzheimer Research 2010; 7 (7) . https://dx.doi.org/10.2174/156720510793499011
DOI https://dx.doi.org/10.2174/156720510793499011 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Superior Neuroprotective Effects of Cerebrolysin in Nanoparticle-Induced Exacerbation of Hyperthermia-Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets The Clinical Neuroscience of Post Stroke Depression
Current Neuropharmacology Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Modulation Effects of Piracetam and Ginkgo biloba on the Cognitive and Working Memory Functions: Psychometric Study
Current Psychopharmacology Clinical Pharmacology of Current and Future Drugs for the Acute Treatment of Migraine: A Review and An Update
Current Clinical Pharmacology Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Tualang Honey and its Methanolic Fraction Improve LPS-induced Learning and Memory Impairment in Male Rats: Comparison with Memantine
Current Nutrition & Food Science Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Current Alzheimer Research Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells
Current Pharmaceutical Design Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Protection by Nigella Sativa [Black Seed] against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Developments in HIV Neuropathogenesis
Current Pharmaceutical Design Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Current Vascular Pharmacology Editorial (Thematic Issue: Treating Major Age-Related Diseases in Older and Oldest Old Patients)
Current Pharmaceutical Design Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design